The ability of prostate cancer cells to bypass the androgen requirement is multifactorial, but often includes alterations to the androgen receptor (AR), intratumoral androgen stimulation, or crosstalk with alternate pathways that ultimately promote reactivation of AR [7, 8]. The gene discussed is AR; the disease is prostate cancer.